Drug intelligence / Profile preview

ARTZEN

Development stage: Unknown
Lead developer: Vasolife Healthcare
Modality: Small Molecules
Administration: Oral

Overview

ARTZEN is a line of atorvastatin-based pharmaceutical products marketed by Vasolife Healthcare, primarily used for the management of hyperlipidemia and the reduction of cardiovascular disease risk. The active ingredient, atorvastatin, is a small molecule HMG-CoA reductase inhibitor that reduces hepatic cholesterol synthesis, thereby lowering systemic LDL cholesterol and triglyceride levels. The product range includes standalone atorvastatin (ARTZEN) and fixed-dose combinations such as ARTZEN-F, which includes the PPAR-alpha agonist fenofibrate. These oral formulations are marketed as branded generics in the Indian market.

Brand names: ARTZENARTZEN-F
Other names: atorvastatin

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on ARTZEN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARTZEN.

Explore the full profile